Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | protease, serine, 1 (trypsin 1) | Starlite/ChEMBL | References |
Homo sapiens | coagulation factor II (thrombin) | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Trypsin family protein | protease, serine, 1 (trypsin 1) | 247 aa | 287 aa | 21.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | thymidine kinase, putative | 0.0487 | 0.8859 | 0.5 |
Trypanosoma cruzi | thymidine kinase, putative | 0.0487 | 0.8859 | 0.5 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0117 | 0.1338 | 0.1338 |
Loa Loa (eye worm) | hypothetical protein | 0.0117 | 0.1338 | 1 |
Leishmania major | thymidine kinase, putative | 0.0487 | 0.8859 | 0.5 |
Giardia lamblia | Deoxynucleoside kinase | 0.0439 | 0.7877 | 0.8847 |
Trypanosoma brucei | thymidine kinase | 0.0487 | 0.8859 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0117 | 0.1338 | 1 |
Trichomonas vaginalis | thymidine kinase, putative | 0.0487 | 0.8859 | 1 |
Onchocerca volvulus | 0.0117 | 0.1338 | 1 | |
Echinococcus granulosus | thymidine kinase | 0.0543 | 1 | 1 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0124 | 0.1484 | 0.118 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0117 | 0.1338 | 0.1338 |
Schistosoma mansoni | thyroid hormone receptor | 0.0134 | 0.1686 | 0.1686 |
Schistosoma mansoni | NADH-ubiquinone oxidoreductase | 0.0068 | 0.0345 | 0.0345 |
Echinococcus multilocularis | transfer RNA-Ile | 0.0543 | 1 | 1 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0134 | 0.1686 | 0.1389 |
Schistosoma mansoni | thyroid hormone receptor | 0.0134 | 0.1686 | 0.1686 |
Schistosoma mansoni | hypothetical protein | 0.0124 | 0.1484 | 0.1484 |
Echinococcus granulosus | Thymidine kinase 2 mitochondrial | 0.0543 | 1 | 1 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0124 | 0.1484 | 0.118 |
Brugia malayi | Trypsin family protein | 0.0117 | 0.1338 | 1 |
Trichomonas vaginalis | thymidine kinase, putative | 0.0487 | 0.8859 | 1 |
Entamoeba histolytica | thymidine kinase, putative | 0.0487 | 0.8859 | 1 |
Echinococcus multilocularis | thymidine kinase | 0.0543 | 1 | 1 |
Trichomonas vaginalis | thymidine kinase, putative | 0.0487 | 0.8859 | 1 |
Echinococcus multilocularis | thymidine kinase | 0.0543 | 1 | 1 |
Giardia lamblia | Thymidine kinase | 0.0487 | 0.8859 | 1 |
Schistosoma mansoni | thymidine kinase | 0.0543 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Concentration (functional) | = 170 nM | Concentration required to double the APTT of human plasma | ChEMBL. | No reference |
Ki (binding) | = 0.5 nM | Binding affinity towards thrombin was evaluated | ChEMBL. | 9871547 |
Ki (binding) | = 0.5 nM | Binding affinity of the compound against human thrombin | ChEMBL. | No reference |
Ki (binding) | = 0.5 nM | Inhibitory constant evaluated against thrombin (Factor IIa) | ChEMBL. | 14505652 |
Ki (binding) | = 0.5 nM | Binding affinity towards thrombin was evaluated | ChEMBL. | 9871547 |
Ki (binding) | = 0.5 nM | Binding affinity of the compound against human thrombin | ChEMBL. | No reference |
Ki (binding) | = 0.5 nM | Inhibitory constant evaluated against thrombin (Factor IIa) | ChEMBL. | 14505652 |
Ki (binding) | = 570 nM | Binding affinity of the compound against human trypsin | ChEMBL. | No reference |
Ki (binding) | = 570 nM | Inhibitory constant evaluated against trypsin | ChEMBL. | 14505652 |
Ki (binding) | = 570 nM | Binding affinity of the compound against human trypsin | ChEMBL. | No reference |
Ki (binding) | = 570 nM | Inhibitory constant evaluated against trypsin | ChEMBL. | 14505652 |
Ki (binding) | > 20 uM | Binding affinity of the compound against serine protease plasmin | ChEMBL. | No reference |
Ki (binding) | > 20 uM | Binding affinity of the compound against serine protease Tissue type plasminogen activator | ChEMBL. | No reference |
Ki (binding) | > 20 uM | Binding affinity of the compound against serine protease Activated protein C | ChEMBL. | No reference |
Ki (binding) | > 20 uM | Binding affinity of the compound against serine protease plasma kallikrein | ChEMBL. | No reference |
Ki (binding) | > 20 uM | Binding affinity of the compound against serine protease plasma chymotrypsin | ChEMBL. | No reference |
Ki (binding) | > 20 uM | Binding affinity of the compound against serine protease plasmin | ChEMBL. | No reference |
Ki (binding) | > 20 uM | Binding affinity of the compound against serine protease Tissue type plasminogen activator | ChEMBL. | No reference |
Ki (binding) | > 20 uM | Binding affinity of the compound against serine protease Activated protein C | ChEMBL. | No reference |
Ki (binding) | > 20 uM | Binding affinity of the compound against serine protease plasma kallikrein | ChEMBL. | No reference |
Ki (binding) | > 20 uM | Binding affinity of the compound against serine protease plasma chymotrypsin | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.